Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

Autor: Johannes M. Kros, Mathilde C.M. Kouwenhoven, Thierry Gorlia, Charles J. Vecht, Denis Lacombe, Martin J. van den Bent, Marc Frenay, Hans J.J.A. Bernsen, Cees C. Tijssen, Laslo Sipos, H. Haaxma-Reiche, Alba A. Brandes, Marc Sanson, Anouk Allgeier, Martin J B Taphoorn, Wolfgang Grisold, Antoine F. Carpentier

Publikováno v: Journal of Clinical Oncology, 24(18), 2715-2722. American Society of Clinical Oncology
Journal of Clinical Oncology, 24(18), 2715-2722. AMER SOC CLINICAL ONCOLOGY

Purpose Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas. We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c29eb32884121c2b0b2a57a110116a8
https://pure.eur.nl/en/publications/27187c05-1dcc-4dc4-8aee-1117ecf793a2